Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
1315 participants
INTERVENTIONAL
2003-06-30
2005-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Use of Oral Contraceptives (OCs) Containing Dienogest and Risk of Venous Thromboembolism
NCT00523614
Valette (Combined Oral Contraceptive SH T04769G and SH D00659AF) Low Ovulation Inhibition
NCT00471991
Bioavailability Study With Oral Single Dose Administration of Ethinylestradiol and Dienogest
NCT01600274
Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding
NCT00307801
Study of a 4-phasic Oral Contraceptive for the Treatment of Heavy Menstrual Bleeding
NCT01638923
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Bayer Schering Pharma AG, Germany is the sponsor of the trial.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1
Valette (Dienogest/EE30, BAY86-5038)
Oral contraceptive extended cycles
Arm 2
Valette (Dienogest/EE30, BAY86-5038)
Oral contraceptive conventional cycles
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Valette (Dienogest/EE30, BAY86-5038)
Oral contraceptive extended cycles
Valette (Dienogest/EE30, BAY86-5038)
Oral contraceptive conventional cycles
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Any conditions that might interfere with the outcome as well as all contraindications for OC use.
18 Years
40 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bayer Schering Pharma AG
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bayer Study Director
Role: STUDY_DIRECTOR
Bayer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Eberbach, Baden-Wurttemberg, Germany
Höchstadt A. D. Aisch, Bavaria, Germany
Krumbach, Bavaria, Germany
Neubiberg, Bavaria, Germany
Nuremberg, Bavaria, Germany
Hamburg, City state of Hamburg, Germany
Hamburg, City state of Hamburg, Germany
Dietzenbach, Hesse, Germany
Frankfurt am Main, Hesse, Germany
Frankfurt am Main, Hesse, Germany
Frankfurt am Main, Hesse, Germany
Fulda, Hesse, Germany
Kelkheim, Hesse, Germany
Langen, Hesse, Germany
Mühlheim am Main, Hesse, Germany
Hanover, Lower Saxony, Germany
Hanover, Lower Saxony, Germany
Ronnenberg, Lower Saxony, Germany
Neustrelitz, Mecklenburg-Vorpommern, Germany
Gevelsberg, North Rhine-Westphalia, Germany
Gütersloh, North Rhine-Westphalia, Germany
Kirchheimbolanden, Rhineland-Palatinate, Germany
Speyer, Rhineland-Palatinate, Germany
Döbeln, Saxony, Germany
Dresden, Saxony, Germany
Dresden, Saxony, Germany
Leipzig, Saxony, Germany
Leipzig, Saxony, Germany
Leipzig, Saxony, Germany
Wurzen, Saxony, Germany
Bernburg, Saxony-Anhalt, Germany
Blankenburg, Saxony-Anhalt, Germany
Jessen, Saxony-Anhalt, Germany
Magdeburg, Saxony-Anhalt, Germany
Magdeburg, Saxony-Anhalt, Germany
Magdeburg, Saxony-Anhalt, Germany
Magdeburg, Saxony-Anhalt, Germany
Magdeburg, Saxony-Anhalt, Germany
Berlin, State of Berlin, Germany
Berlin, State of Berlin, Germany
Berlin, State of Berlin, Germany
Berlin, State of Berlin, Germany
Berlin, State of Berlin, Germany
Eisenberg, Thuringia, Germany
Gera, Thuringia, Germany
Jena, Thuringia, Germany
Kahla, Thuringia, Germany
Saalfeld, Thuringia, Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
306903
Identifier Type: -
Identifier Source: secondary_id
91227
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.